Association between metabolic disease and cardiovascular risk in patients with schizophrenia treated with antipsychotics

被引：0
|
作者：
Vataire, A. [1 ]
Ferchichi, S. [1 ]
Desroziers, K. [1 ]
Cadi-Soussi, N. [2 ]
Murthy, V. [3 ]
Toumi, M. [4 ]
机构：
[1] Creativ Ceut, Paris, France
[2] Takeda Pharmaceut Int GmbH, Zurich, Switzerland
[3] Takeda Dev Ctr Europe, London, England
[4] Univ Lyon 1, F-69365 Lyon, France
来源：
EUROPEAN NEUROPSYCHOPHARMACOLOGY | 2013年 / 23卷
关键词：
D O I：
10.1016/S0924-977X(13)70785-5
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P.3.f.007
引用
收藏
页码：S495 / S495
页数：1
相关论文
共 50 条
  • [21] Screening for metabolic abnormalities in patients with schizophrenia treated with antipsychotics: are we doing enough?
    Van Winkel, R.
    De Hert, M.
    Van Eyck, D.
    Hanssens, L.
    Wampers, M.
    Scheen, A.
    Peuskens, J.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2006, 16 : S398 - S398
  • [22] Metabolic syndrome and related factors treated with antipsychotics monotherapy and polypharmacy in patients with schizophrenia
    Oncu, Fatih
    Acuner, Tufan T.
    Atlar, Fatmahan
    Turkcan, Solmaz
    Yesilbursa, Dogan
    Uygur, Niyazi
    KLINIK PSIKOFARMAKOLOJI BULTENI-BULLETIN OF CLINICAL PSYCHOPHARMACOLOGY, 2009, 19 : S292 - S295
  • [23] Equally increased risk for metabolic syndrome in patients with bipolar disorder and schizophrenia treated with second-generation antipsychotics
    Correll, Christoph U.
    Frederickson, Anne M.
    Kane, John M.
    Manu, Peter
    BIPOLAR DISORDERS, 2008, 10 (07) : 788 - 797
  • [24] Are cardiovascular disease risk factors affected by antipsychotics in patients with schizophrenia? What qrisk-3 points?
    Aydin, M.
    Altinbas, K.
    Bozkurt, H. T.
    EUROPEAN PSYCHIATRY, 2019, 56 : S246 - S247
  • [25] Assessment and control of metabolic and cardiovascular risk in patients with schizophrenia
    Rodriguez-Artalejo, Fernando
    Baca, Enrique
    Esmatjes, Enrique
    Merino-Torres, Juan Francisco
    Monereo, Susana
    Moreno, Basilio
    Mories, Teresa
    Roca, Miquel
    Salvador, Javier
    Sanmarti, Anna
    MEDICINA CLINICA, 2006, 127 (14): : 542 - 548
  • [26] Cardiovascular risk factors and metabolic syndrome in patients treated with long-acting injectables antipsychotics: a retrospective study
    De Carlo, Vera
    Grancini, Benedetta
    Cassina, Niccolo
    Casati, Lorenzo
    Piccoli, Eleonora
    Vismara, Matteo
    Gobbo, Dario
    Zanaschi, Raffaella
    Lupo, Susanna
    Olivieri, Silvia
    Dell'Osso, Bernardo
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2023, 38 (03) : 160 - 168
  • [27] Association of antipsychotics adherence and cardiovascular disease among newly diagnosed schizophrenia patients: A national cohort among Koreans
    Chang, Jooyoung
    Kim, Jihoon Andrew
    Kim, Kyuwoong
    Choi, Seulggie
    Kim, Sung Min
    Nam, Yoon-Young
    Park, Subin
    Goo, Ae Jin
    Park, Sang Min
    ASIAN JOURNAL OF PSYCHIATRY, 2020, 52
  • [28] LOW RATES OF TREATMENT OF CARDIOVASCULAR RISK FACTORS IN PATIENTS TREATED WITH ANTIPSYCHOTICS
    van der Heijden, F.
    Steylen, P.
    Kok, H.
    Slaar, A.
    Verhoeven, W.
    EUROPEAN PSYCHIATRY, 2011, 26
  • [29] Metabolic Syndrome and Cardiovascular Risk in People Treated with Long-Acting Injectable Antipsychotics
    Sanchez-Martinez, Vanessa
    Romero-Rubio, Dolores
    Jose Abad-Perez, Maria
    Amparo Descalzo-Cabades, Maria
    Alonso-Gutierrez, Sofia
    Salazar-Fraile, Jose
    Montagud, Vicente
    Facila, Lorenzo
    ENDOCRINE METABOLIC & IMMUNE DISORDERS-DRUG TARGETS, 2018, 18 (04) : 379 - 387
  • [30] Cardiovascular Disease Risk Profile in Patients with Schizophrenia
    Brobakken, Mathias F.
    Nygaard, Mona
    Guzey, Ismail Cuneyt
    Morken, Gunnar
    Wang, Eivind
    Heggelund, Jorn
    Vedul-Kjelsas, Einar
    MEDICINE AND SCIENCE IN SPORTS AND EXERCISE, 2017, 49 (05): : 432 - 432
12345